Jazz Pharmaceuticals (JAZZ) to Release Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) will post its quarterly earnings results after the market closes on Wednesday, May 1st. Analysts expect Jazz Pharmaceuticals to post earnings of $3.55 per share for the quarter. Jazz Pharmaceuticals has set its FY24 guidance at $18.15-$19.35 EPS and its FY 2024 guidance at 18.150-19.350 EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. On average, analysts expect Jazz Pharmaceuticals to post $16 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Stock Up 1.6 %

Shares of JAZZ opened at $111.22 on Tuesday. The company has a market capitalization of $7.01 billion, a price-to-earnings ratio of 18.17, a PEG ratio of 1.51 and a beta of 0.59. Jazz Pharmaceuticals has a 52 week low of $106.61 and a 52 week high of $146.70. The stock’s 50-day moving average price is $117.94 and its 200-day moving average price is $121.57. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent analyst reports. Stifel Nicolaus increased their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Robert W. Baird assumed coverage on Jazz Pharmaceuticals in a report on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 target price on the stock. HC Wainwright decreased their target price on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating on the stock in a report on Thursday, March 14th. UBS Group lowered their price objective on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research report on Friday, March 1st. Finally, Truist Financial reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $195.08.

Insiders Place Their Bets

In other news, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were acquired at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO Philip L. Johnson bought 12,000 shares of the stock in a transaction on Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.